# Thermosensitive Chitosan/Gelatin Hydrogels in Traditional Chinese Veterinary Medicine: A Prospective Review on Modernizing Acupoint Embedding

**Authors:** Yingying Xie, Xuequan Hu, Ying Li, Jianfa Wang, Rui Wu

PMC · DOI: 10.3390/gels12030193 · 2026-02-26

## TL;DR

This paper explores how thermosensitive chitosan/gelatin hydrogels could modernize traditional veterinary acupuncture by enabling targeted drug delivery and improved biocompatibility.

## Contribution

The paper proposes and analyzes the novel use of thermosensitive hydrogels for acupoint embedding in veterinary medicine, addressing limitations of traditional methods.

## Key findings

- Chitosan/gelatin hydrogels offer tunable gelation and degradation properties suitable for diverse animal species.
- These hydrogels show potential for treating piglet diarrhea, canine joint disease, and equine laminitis via acupoint embedding.
- Current challenges include formulation optimization and understanding long-term safety in veterinary applications.

## Abstract

Thermosensitive hydrogels have emerged as promising intelligent biomaterials for minimally invasive delivery and targeted therapy. Chitosan/gelatin thermosensitive hydrogels, integrating the biocompatibility, biodegradability, and antibacterial activity of chitosan with the excellent adhesive properties of gelatin, exhibit unique injectability, temperature-responsive gelation, and tunable physicochemical properties. This review systematically summarizes the key performance parameters of chitosan/gelatin thermosensitive hydrogels, including injectability, gelation characteristics (with sol-gel transition tunable between 37 and 42 °C to match diverse species’ body temperatures), mechanical properties, biocompatibility, degradation behavior (tunable from 1 to 8 weeks), drug-loading/release capabilities, and multi-stimuli responsiveness (pH/ROS/enzyme). It focuses on exploring their feasibility and suitability as acupoint embedding materials in Traditional Chinese Veterinary Medicine (TCVM), addressing the technical bottlenecks of traditional acupoint catgut embedding (e.g., unstable degradation, insufficient biocompatibility, and lack of drug-loading capacity). While recent studies have demonstrated the utility of such hydrogels in human disease models (e.g., rheumatoid arthritis and Parkinson’s disease), their translation to veterinary acupoint therapy remains largely unexplored. The prospective application of these hydrogels in treating common animal diseases (e.g., piglet diarrhea, canine degenerative joint disease, and equine laminitis) is, therefore, proposed and analyzed as an illustrative paradigm, emphasizing its integrated “stimulation–drug delivery” function and cross-species adaptability. Additionally, the current challenges (e.g., animal-specific formulation optimization, unclear mechanism of action, and insufficient long-term safety data) and future research directions (e.g., veterinary-specific formulation development, mechanistic exploration, and clinical translation) are highlighted. This review aims to promote the interdisciplinary integration of TCVM and smart biomaterials, provide precision strategies for animal disease treatment, and ultimately contribute to the modernization and standardization of TCVM technologies.

## Linked entities

- **Diseases:** rheumatoid arthritis (MONDO:0008383), Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Genes:** TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, TNF-alpha [NCBI Gene 100033834], IL-6 [NCBI Gene 100034196], Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 449622] {aka SDF1}, TNF (tumor necrosis factor) [NCBI Gene 403922] {aka TNFA, TNLG1F, cTNF}, Fgf2 (fibroblast growth factor 2) [NCBI Gene 14173] {aka Fgf-2, Fgf2a, Fgfb, bFGF}, CEACAM1 (CEA cell adhesion molecule 1) [NCBI Gene 634] {aka BGP, BGP1, BGPI}, IL6 (interleukin 6) [NCBI Gene 403985] {aka IL-6}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 403998], TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 445457] {aka VR1}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}
- **Diseases:** numbness (MESH:D006987), gastrointestinal damage (MESH:D005767), diabetic (MESH:D003920), neurological disease (MESH:D020271), ischemia (MESH:D007511), RA (MESH:D001172), degenerative osteoarthritis (MESH:D010003), degenerative joint disease (MESH:D019636), muscle relaxants (MESH:D019042), pain (MESH:D010146), Cytotoxicity (MESH:D064420), immune dysfunction (MESH:D007154), PD (MESH:D010300), arthritic (MESH:D015535), spinal cord injury (MESH:D013119), neuroinflammation (MESH:D000090862), back muscle spasms (MESH:D013035), depression (MESH:D003866), antibiotic abuse (MESH:D004761), obese (MESH:D009765), intervertebral disc disease (MESH:C535531), glaucoma (MESH:D005901), myofasciitis (MESH:D009209), injury (MESH:D014947), bleeding (MESH:D006470), infection (MESH:D007239), swelling (MESH:D004487), Bi syndrome (MESH:D013577), mastitis (MESH:D008413), inflammation (MESH:D007249), lameness (MESH:D007794), burn (MESH:D002056), infectious disease (MESH:D003141), Piglet diarrhea (MESH:D003967), breast cancer (MESH:D001943), TCVM (MESH:C562377), pressure ulcer (MESH:D003668), fibrosis (MESH:D005355), cancer (MESH:D009369), joint pain (MESH:D018771), viral diarrhea (MESH:D014777), hemolysis (MESH:D006461)
- **Chemicals:** glucosamine (MESH:D005944), HA (MESH:D006820), laponite (MESH:C524813), DXM (MESH:D003907), doxorubicin (MESH:D004317), polysaccharide (MESH:D011134), CS (MESH:D048271), meloxicam (MESH:D000077239), berberine (MESH:D001599), PLGA (MESH:D000077182), carbon nanotubes (MESH:D037742), PCL (MESH:C016240), beta-glycerophosphate (MESH:C031463), PVA (MESH:D011142), KCl (MESH:D011189), celecoxib (MESH:D000068579), hydrogen (MESH:D006859), curcumin (MESH:D003474), methocarbamol (MESH:D008721), CB-nHA (-), HPMC (MESH:D065347), polymer (MESH:D011108), water (MESH:D014867), SiO2 (MESH:D012822), MTT (MESH:C070243), glucose (MESH:D005947), phenylboronic acid (MESH:C010686), PMAA (MESH:C030613), montmorillonite (MESH:D001546), Levofloxacin (MESH:D064704), MLT (MESH:D008550), kappa-carrageenan (MESH:D002351), alginate (MESH:D000464), chondroitin sulfate (MESH:D002809), triptolide (MESH:C001899), flunixin meglumine (MESH:C014558), genipin (MESH:C007834), HBC (MESH:C000626207), EDC&amp;NHS (MESH:C000625275), Glu (MESH:D018698), N-Hydroxysuccinimide (MESH:C001426), PBA (MESH:C075773), MC (MESH:D008747), AA (MESH:D000596), TNZ (MESH:D014011), polyurethane (MESH:D011140), 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (MESH:D005022), ROS (MESH:D017382), carboxymethyl chitosan (MESH:C514968), polydopamine (MESH:C568283), praziquantel (MESH:D011223), L-lysine (MESH:D008239)
- **Species:** Homo sapiens (human, species) [taxon 9606], Gallus gallus (bantam, species) [taxon 9031], Bos taurus (bovine, species) [taxon 9913], Rodentia (rodent, order) [taxon 9989], Mus musculus (house mouse, species) [taxon 10090], Sus scrofa (pig, species) [taxon 9823], Escherichia coli (E. coli, species) [taxon 562], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Equus caballus (domestic horse, species) [taxon 9796], Rattus norvegicus (brown rat, species) [taxon 10116], Canis lupus familiaris (dog, subspecies) [taxon 9615]
- **Cell lines:** MCF-10 — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0598), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025340/full.md

---
Source: https://tomesphere.com/paper/PMC13025340